Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
JC Gallagher, SH Tella - Clinical obstetrics and gynecology, 2013 - journals.lww.com
… In 2013, we believe that in the early postmenopause, that is, within 5 to 10 years of
menopause, ET and HT should still be considered as first-line therapy for preventing bone
loss, especially in women who have vasomotor symptoms or vaginal atrophy, whereas
SERMs and bisphosphonates do not treat these symptoms. However, in older patients over
the age 60 years with osteoporosis or significant osteopenia, bisphosphonates should be
the first choice. SERMS are usually a second … However, in our opinion, there may be …
menopause, ET and HT should still be considered as first-line therapy for preventing bone
loss, especially in women who have vasomotor symptoms or vaginal atrophy, whereas
SERMs and bisphosphonates do not treat these symptoms. However, in older patients over
the age 60 years with osteoporosis or significant osteopenia, bisphosphonates should be
the first choice. SERMS are usually a second … However, in our opinion, there may be …
以上显示的是最相近的搜索结果。 查看全部搜索结果